United-Guardian Inc

Aktienanalyse zu United-Guardian Inc (UG)

$6.780

-0.020 (-0.29%)Zum Schluss

Loading chart…
Hoch
6.885
Eröffnung
6.690
Volumengewichteter Durchschnittskurs
6.77
Volumen
16.51K
Marktkap.
42.64M
Tief
6.650
Umsatz
111.82K
EV/EBITDA, TTM
0.00

United-Guardian, Inc. is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants. The Company’s product lines include the Lubrajel line of multifunctional hydrogel formulations, which are designed to provide sensory enhancement, lubrication, hydration, and texture to both personal care and medical products. Its four distinct product categories include cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. Its COSMOS line of products includes Lubrajel Natural, Lubrajel Marine, Lubrajel Oil Natural, and Lubrajel Terra. Its medical lubricants include a line of hydrogel formulations designed to offer sensory enhancement and lubrication to medical products. The Company’s pharmaceutical products include an FDA-approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial.

u-g.com

KI-Analyse of United-Guardian Inc (UG)

Halten

United-Guardian Inc is currently not a strong buy due to mixed performance indicators. The current price is $6.78, with an RSI of 40.69 indicating a neutral momentum. The forward P/E ratio is 26.53, suggesting that the stock may be overvalued relative to its earnings potential. However, the company has shown a year-to-date change of +10.60%, indicating some resilience. The main risk is the recent revenue decline of 13.5% year-over-year, attributed to market challenges, which could impact future profitability.

Bewertungskennzahlen

Das aktuelle erwartete KGV von United-Guardian Inc (UG) beträgt 26.53, verglichen mit dem 5-Jahres-Durchschnitt von 4.61.

Erwartetes KGV

Stark überbewertet
5J-Durchschnitt P/E
4.61
Aktuelles P/E
26.53
Überbewertet
14.78
Unterbewertet
-5.56

Erwartetes EV/EBITDA

Stark unterbewertet
5J-Durchschnitt EV/EBITDA
0.00
Aktuelles EV/EBITDA
0.00
Überbewertet
0.00
Unterbewertet
0.00

Erwartetes KUV

Stark unterbewertet
5J-Durchschnitt P/S
0.00
Aktuelles P/S
0.00
Überbewertet
0.00
Unterbewertet
0.00

Alphio-AI-Kursszenarien für UG

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%UG

$13.06

Szenariopreis

B

Basis

Basis · 50%UG

$11.05

Szenariopreis

B

Bärisch

Bärisch · 25%UG

$10.96

Szenariopreis

Event-Zeitleiste

2025-11-06 (ET)

09:04:50

United-Guardian Announces Q3 Earnings Per Share of 6 Cents Compared to 19 Cents Last Year

2025-08-08 (ET)

09:05:14

United-Guardian reports Q2 EPS 14c vs 21c

2025-05-21 (ET)

09:05:44

United-Guardian appoints Donna Vigilante to board of directors

2025-05-08 (ET)

09:03:12

United-Guardian reports Q1 EPS 12c vs 20c last year

2025-03-21 (ET)

09:04:32

United-Guardian reports FY24 EPS 71c vs 56c last year

News

UG FAQ – beantwortet von Alphio AI

United-Guardian, Inc. is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants. The Company’s product lines include the Lubrajel line of multifunctional hydrogel formulations, which are designed to provide sensory enhancement, lubrication, hydration, and texture to both personal care and medical products. Its four distinct product categories include cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. Its COSMOS line of products includes Lubrajel Natural, Lubrajel Marine, Lubrajel Oil Natural, and Lubrajel Terra. Its medical lubricants include a line of hydrogel formulations designed to offer sensory enhancement and lubrication to medical products. The Company’s pharmaceutical products include an FDA-approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial. It operates in the Healthcare sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

United-Guardian Inc is currently not a strong buy due to mixed performance indicators. The current price is $6.78, with an RSI of 40.69 indicating a neutral momentum. The forward P/E ratio is 26.53, suggesting that the stock may be overvalued relative to its earnings potential. However, the company has shown a year-to-date change of +10.60%, indicating some resilience. The main risk is the recent revenue decline of 13.5% year-over-year, attributed to market challenges, which could impact future profitability.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln